![]() Horizon Therapeutics Horizon Therapeutics (formerly known as Horizon Pharma) is a biopharmaceutical company focused on researching, developing, and commercializing medicines. | ![]() Amarin Amarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases. | ![]() Cartesian Therapeutics Cartesian Therapeutics (formerly Selecta Biosciences) is a clinical-stage biopharmaceutical company advancing a differentiated product pipeline to modulate the immune system. | ![]() Avrobio Clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. | ![]() Arcturus Therapeutics Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company. | ![]() Aeglea Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics. | |||
Founding Date | Founding Date 2008 | Founding Date 2014 | Founding Date 1991 | Founding Date 2007 | Founding Date 2010 | Founding Date N/A | Founding Date 2013 | Founding Date 2013 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||
Locations | Locations Dublin, IE HQ | Locations London, GB HQ Basel, CH Boston, US New York, US | Locations Dublin, IE HQ Zug, CH Bridgewater Township, US | Locations Watertown, US HQ | Locations Cambridge, US HQ | Locations San Diego, US HQ | Locations Austin, US HQ | |
Employees | Employees 2,6691% increase | Employees 908 | Employees 275 | Employees 15 | Employees 1,2763% decrease | Employees 8573% increase | Employees 170 | Employees 6932% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 8.8 b | Valuation ($) 257.6 m | Valuation ($) 536.3 m | Valuation ($) 4.9 b | Valuation ($) 5.2 m | Valuation ($) 529.2 m | Valuation ($) 48.6 m |
Financial | ||||||||
Revenue (est.) | Revenue (est.) $3.6b (FY, 2022) | Revenue (est.) $124.8m (FY, 2023) | Revenue (est.) $228.6m (FY, 2024) | Revenue (est.) $38.9m (FY, 2024) | Revenue (est.) $560.2m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $152.3m (FY, 2024) | Revenue (est.) N/A |
Gross profit | Gross profit $2.7b (FY, 2022) | Gross profit N/A | Gross profit $81.4m (FY, 2024) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income $521.5m (FY, 2022) | Net income $4.2b (FY, 2023) | Net income ($82.2m) (FY, 2024) | Net income ($77.4m) (FY, 2024) | Net income ($569.2m) (FY, 2024) | Net income ($58m) (FY, 2024) | Net income ($80.9m) (FY, 2024) | Net income ($208m) (FY, 2024) |
Operating ⚠ | ||||||||
Phase I Trials Products | Phase I Trials Products 3 (Sep, 2021) | Phase I Trials Products 4 (Q2, 2021) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 12 (Sep, 2021) | Phase II Trials Products 5 (Q2, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 2 (Sep, 2021) | Phase III Trials Products 1 (Q2, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | ||||||||
Total funding raised | Total funding raised $ 63m | Total funding raised $ 1.9b | Total funding raised $ 122.8m | Total funding raised $ 167.7m | Total funding raised $ 200.1m | Total funding raised $ 85m | Total funding raised N/A | Total funding raised N/A |
Roivant Sciences is a company that develops and commercializes medicines.
View companyAmarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases.
View companyCartesian Therapeutics (formerly Selecta Biosciences) is a clinical-stage biopharmaceutical company advancing a differentiated product pipeline to modulate the immune system.
View companyUltragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.
View company